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Abstract 
Objective: Design of Experiment (DoE), that is a tool of Quality by Design (QbD) paradigm, 
with which experiments can be planned more effectively and provide more information, while 
after Design Space (DS) can be set up, which assure the quality of the desired product. The 
aim of this study was to find the optimal drug-excipient ratio and the optimal process 
parameters (milling time, milling speed) of our previously used dry co-milling method and 
validate the DS. 
Materials and Methods: Lamotrigine (LAM), an antiepileptic drug was used as a model API. 
Poly-vinyl alcohol (PVA) was chosen according to our previous study as a hydrophylic matrix 
polymer. Milling time, speed and the API: additive ratio was varied to find out their effect on 
the product. The optimization was performed on particle size of LAM, its Standard Deviation 
and the in vitro dissolution of the samples. Response Surface Modeling completed the 
statistical analysis that assessed the effects of independent variables on the responses. 
Results: Due to the DS estimation a more economical sample preparation method was set up. 
Finally, the sample that was prepared according to the optimized parameters (1.5 h, 400 rpm, 
0.8 PVA: LAM ratio) showed around 100 nm drug particles and 97% drug release in 5 
minute. 
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Conclusion: From the DS generated by the software, an optimal formulation was obtained and 
the results validated the experimental design. The QbD approach was a useful and effective 
tool of understanding the parameters that affect the quality of the desired product.  
Keywords: Design Space, nasal powder, dry milling, nanoparticle, lamotrigine 
 
1. Introduction 
In the last few decades dry milling - a top-down method to prepare particles with 
decreased size- has become a popular technology in pharmaceutical industry. Due to the 
rising number of poorly water-soluble drug candidates it is necessary to use methods, which 
improve the water solubility and dissolution rate of these drugs, that can lead to increased 
bioavailability [1, 2]. There are some other options to improve these attributions such as 
liposomes, co-solvents, amorphous solid dispersions, pro-drugs, complexation, cyclodextrin 
inclusion, self emulsification, etc. [3, 4]. Milling is an optimal method for particle size 
reduction, because of its simplicity, cheapness and well plannability [5]. It is also an 
environmentally and economically desirable method, as during the process no organic solvent 
is needed, that has potential toxicity issues and there is no significant loss of materials [6]. 
The industrial application of co-milling is also common -not just in pharmaceutical industry, 
but also in e.g. food industry- as it can be starting, intermediate or finishing process. The 
approach is also a more gentle method compared to temperature dependent or solvent 
evaporation technologies, because during the process the heat does not damage the materials, 
so in most cases decomposition does not occur [7]. 
Dry powder formulations are becoming widespread nowadays (oral powders, dry 
powder inhalations, nasal powders). The reason of the increasing number of formulations is 
that they offer better physicochemical and microbiological stability than liquid formulations. 
As a result preservatives are not needed and also the unexpected incompatibilities are not 
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common. Their shelf life is longer and the transport is much easier, but packaging must ensure 
protection against humidity and light [8-12].  
By using nasal powders local, systemic and CNS (Central Nervous System) effect can 
be achieved as the API can get in direct contact with the olfactory and respiratory epithelium. 
The nasal cavity can be divided into two main regions: the olfactory - and the respiratory 
region.  The mucosa of the respiratory region is responsible for respiration, the regulation of 
humidity and temperature of inhaled air as well. The olfactory region, which is responsible for 
olfaction, is located high in nasal cavity. It overlies the cribiform plate, that has bony structure 
with many pores. These pores allow the neuronal bandles from the olfactory region to pass 
into the CNS. However, it is important to note that beside olfactory nerve, CNS effect can be 
achieved via trigeminal nerve. It is possible, because the neurons from the branches of 
trigeminal nerve pass directly through the mucosa. Via the respiratory region the API can 
absorb through the GI tract, the lungs or directly to the systemic circulation from which it is 
delivered to the CNS [13-15].  Intranasal powders can ensure higher administered dose 
compared to liquid forms, extended residence time in the nasal cavity due to their better 
adhesion, and better absorption ability through the nasal mucosa. However, the efficiency of a 
nasal powder is up to its dissolution rate in the nasal mucosa [16-18]. The dissolution 
properties can be improved via numerous ways such as complexation with cyclodextrines or 
nanonization [19, 20]. By using nanoparticles the enhanced surface of the particles leads to 
rapid dissolution, fact that our research group has proved previously with powders that 
contained nanosized meloxicam [22].  As lamotrigine (LAM) is only available in tablet form 
on market, it is desirable to develop nasal dosage forms of LAM as alternative drug 
administration to treat those situations when oral administration is not possible (e.g. 
absorption disorder, unconsciousness or in crisis therapy for rapid onset). Nasal powders are 
suitable –beside their advantages mentioned above-, to target directly the brain, therefore 
LAM can results faster effect as its administration. The dissolution extent of LAM can also be 
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improved by using poly-vinyl alcohol (PVA) and due to the decrease of crystallinity of LAM 
[21]. The improved properties contribute to the fast dissolution and therefore to a rapid onset 
of action that are important properties of nasal products, especially powders [22]. In order to 
get these features, it is important to know all the main influencig process and formulation 
parameters and their effect on the desired product. 
To find the right parameters Quality by Design (QbD) can be an option. This is a 
holistic approach within the development design based on knowledge and risk. With QbD the 
experimental runs can be planned more economically and efficiently [23-28]. Design of 
Experiment (DoE), a tool of QbD paradigm is a systematic approach. It allows to find optimal 
product and/or process parameters usually providing larger amount of information from less 
number of experimental runs. It is available by varying the factors and simultaneously 
evaluating the effect of multiple variables. DoE is also useful to identify the individual and 
interacting factors. Using response surface methodology may lead to the development of 
Design Space (DS), which assure the quality of the desired product and can be defined for 
both the formulation and process parameters [29-31]. 
In our previous study, where the aim was to produce nanonized LAM containing nasal 
powder, an initial Risk Assessment (RA) was applied [32]. It was found out that among the 
Critical Quality Attributes (CQAs) the particle size, its distribution and the dissolution rate of 
LAM, while among the Critical Process Parameters (CPPs) the milling time, the speed and a 
critical formulation parameter, the LAM: additive ratio influence mostly the quality of the 
desired product. Though there are some publications that investigated nanosystems by using 
QbD [24, 33-35], but to the best of our knowledge there are no study on powders that are 
containing nanoparticles. The combination of the advantages of nanoparticles and nasal 
powders can be a promising opportunity for the treatment of different CNS diseases and that 
is why optimal production parameters are required.  
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The aim of this study was to identify the DS by optimizing the parameters of a 
previously used dry milling method. The parameters were chosen according to preliminary 
tests and literature data. DS also allows to secure the quality of our samples and helps to find 
the optimal formulation for producing nasal powder formulation containing nanonized LAM 
particles. PVA was chosen according to our previous study, as a hydrophylic matrix polymer 
to prevent the nanoparticles from aggregation [32]. Because the fast dissolution is a critical 
parameter for nasal administration, the main aim was to reach nearly 100% drug release by 
production of nanoparticles of LAM.  
 
2. Materials and Methods 
2.1. Materials  
Lamotrigine (LAM), poorly water soluble (0.17 mg/ml at 25 °C) second-generation 
antiepileptic drug of the phenyltriazine class, was purchased from Teva Ltd. (Budapest, 
Hungary). Poly-vinyl alcohol (PVA) (Mw= 27000), water-soluble synthetic polymer –that was 
applied to stabilize the unique drug particles thus improving their absorption- was supplied by 
ISP Customer Service GmBH (Cologne, Germany). 
2.2. Experimental methods 
2.2.1. Experimental Design 
In our previous study the QTPP (Quality Target Product Profile) had been defined. 
The most desired product characteristics were the nanoparticle size (50-200 nm) with narrow 
size distribution and rapid dissolution of LAM. In fact, this means that the drug nanoparticles 
are in direct contact with the mucosa using PVA resulted in fast dissolving depot with 
increased saturation solubility. To map the most critical factors on these characteristic 
properties, an Ishikawa diagram and initial RA was set up to identify the CQAs as well as the 
CPPs. As a result of RA results it was found that among the CQAs the particle size and 
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dissolution rate of LAM, while among the CPPs the milling time, the milling speed and the 
API/ additive ratio have the greatest influence on the quality of our desired product [32]. 
To determine the optimal process parameters a full factorial design was set up with 3 
factors on 3 levels, using MODDE 11.1 software (Umetrics, Sweden). The software generated 
27 experimental runs as well as 3 center points used to calculate the degrees of freedom, the 
reproducibility. The milling time (X1), milling speed (X2) and the PVA: LAM (m/m %) ratio 
(X3) were selected as input variables indicated by RA. To characterize the powders the 
following responses were chosen according to RA: average particle size of LAM (Y1) and its 
standard deviation (Y2), the percentage of dissolved LAM from the samples after 5 (Y3) and 
10 minutes (Y4). The factor variation levels and the acceptable ranges of CQAs were chosen 
based on our previous study, prior knowledge and relevant literature (Table 1.) [32]. The data 
fitting and the statistical parameters determination were done using the same DoE software. 
The effects of the independent variables were modelled using the Partial Least Squares 
method. ANOVA test was applied to evaluate the significance of models (p < 0.05).  
For regression analysis the goodness of fit, capacity of prediction, model validity, and 
reproducibility were considered. The goodness of fit of a model is given by the value of R2 
and represents the variation of the response explained by the model. Q2 represents the 
goodness of prediction and reveals how well the model can predict new experiments [30]. 
Model validity provides insights regarding the model error, while reproducibility (pure 
error) evaluates the variation of response under identical conditions compared to its total 
variation. Model validity parameter relies on lack of fit test carried out in ANOVA, and for its 
calculation the p values is used. When there is no lack of fit (p>.05), the validity parameter 
will be above 0.25. Reproducibility is computed according to Equation (1). 
Reproducibility = 1 – MS pure error/MS total corrected 
Equation 1. Reproducibility calculation 
MS variance 
 7
Response contour plots were generated to allow illustrate the relationship between the 
different experimental variables and the responses. The establishment of a DS is based on the 
regression model and an estimation of the probability for failure. Monte Carlo simulations are 
used to compile the necessary probability statistics and risk analysis. The probability of 
getting predictions outside the response specifications were expressed as DPMO (defects per 
million opportunities). The result variation is a function of the number of simulations used; 
the more simulations, the better reproducibility. In this study the settings were 20000 
simulations for the factor range estimation and 50000 simulations for the final prediction. In 
order to evaluate the validity of the experimental design, optimum formulation were selected 
from the Design Space and the measured experimental values were compared to the predicted 
ones. When searching for a solution limited by many criteria, the result will be a compromise 
between those criteria. Finally, based on experimental results, the Design Space (DS) was 
determined.  
2.2.2. Preparation of lamotrigine containing nasal powders and proven acceptable range 
(PAR) determination 
PVA was used as an additive during the sample preparation process to maintain the 
stability and individuality of LAM particles. The given amount of PVA and LAM were mixed 
in a Turbula mixer (Turbula System Schatz; Willy A. Bachofen AG Maschinenfabrik, Basel, 
Switzerland) using 60 rpm for 10 minutes. After mixing, 1 gram of sample was placed into a 
planetary ball mill (Retsch PM 100; Retsch, Neuhausen, Germany) and milled in a 50 mL 
capacity milling chamber. For milling, 10 steel balls (diameter 10 mm, weight of each ball 
4.02 g) were used to get the co-milled samples. Table 1. shows the factors and their variation 
levels along with the chosen responses and their values.  
The proven acceptable range (PAR) - that was generated by the software - according 
to the ICH Q8 guideline is „a characterized range of a process parameter for which operation 
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within this range, while keeping other parameters constant, will result in producing a material 
meeting relevant quality criteria.” The PAR of all responses are also indicated in Table 1.
 
Table 1. The parameters of milling, the chosen responses and their values 
 
2.3. Particle size determination with scanning electron microscopy (SEM) 
The morphology of the powder microparticles was investigated by SEM (Hitachi 
S4700; Hitachi Ltd., Tokyo, Japan) at 10 kV. The samples were gold–palladium coated (90 
seconds) with a sputter coater (Bio-Rad SC502; VG Microtech, Uckfield, UK) using an 
electric potential of 2.0 kV at 10 mA for 10 minutes. The air pressure was 1.3–13.0 mPa. 
Distributions of LAM particle diameter were obtained by analyzing SEM images with the 
ImageJ software (1.50i; Java 1.6.0_20 [32-bit]; Windows NT) environment using 
approximatively 500 particles.  
2.4. In vitro dissolution studies 
The modified paddle method (USP dissolution apparatus, type II; Pharma Test, 
Hainburg, Germany) was used to examine the dissolution rate of LAM-containing co-milled 
nasal powders and determine the drug release profile from the samples. The test was carried 
out under nasal conditions for temperature and pH. The medium was 100 mL phosphate 
buffer (PBS of pH 5.60 at 30°C), in which 108 mg of the samples were tested. The paddle 
was rotated at 50 rpm, and the sampling points were at 5 minutes, 10 minutes, 15 minutes, 30 
minutes and 60 minutes. In the beginning the sampling point were more frequent, because the 
beginning of the investigation is more important as the mucociliary clearance renew the 
mucus in every 15 minutes [16]. The following sampling points offered extra information 
about the dissolution behaviour of LAM. After filtration, the drug contents of the aliquots 
were determined using spectrophotometry (Unicam UV/VIS Spectrophotometer) at 296 nm. 
The tests were carried out in triplicates. 
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3. Results and Discussion 
3.1. DoE analysis, summary of fit 
The results of the experiments and the measured responses can be seen in 
Supplementary table 1. It can be observed that the high milling time, speed and LAM: PVA 
ratio do not always result small particle size, standard deviation and high dissolved amount of 
LAM. 
To check the validity of the experimental design, the following statistical parameters 
were determined: R2, Q2, model validity and reproducibility. The values of these parameters 
are presented in Table 2. All responses were fitted and well predicted by the model as R2 
values were at least 0.8 and all the Q2 values were above 0.5. The validity value of the models 
were above 0.25 in each case, that indicates good model. The reproducibility values were also 
presume that the process is well-reproducible as they were above 0.9. Model significance 
tested using ANOVA generated lower than 0.05 p values for all responses. Also there was no 
lack of fit detected, as the model error was not significantly different from the replicate error 
(p>0.05) (Table 2.).  
Table 2. Summary of fit for DoE, ANOVA Test results for model significance and lack of fit (p 
values) 
 
3.2. Effect of the milling parameters on the responses 
After evaluating the coefficient plots (Figure 1.) it can be seen that milling time and 
speed have effect on Y1. As the milling time and speed increase, the particle size of the API 
decreases, so it can be concluded that these parameters influence mostly Y1 and Y2. The 
values of LAM size were between 172 nm and 7015 nm. There were some samples, where the 
particles aggregated due to the inappropriate parameters, so the detection of unique particles 
was not possible. 
The same phenomenon was observed in the case of Y2. The increasing milling time 
and speed decreased Y2. This is related to the smaller particle size, because the particles 
became more unique, no aggregation occurred, so the particle size determination was more 
simple above certain parameter values. In the coefficient plot of SD a significant interaction 
could be observed, but its interpretation is possible after the examination of the surface plots. 
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The Y3 and Y4 values increased due to the increased values of the milling parameters. 
The reason of this tendency is that the small particles can leave the matrix easier than bigger 
ones and also the bigger surface due to reduced particle size also advantageous, if the aim is 
rapid dissolution. However, in these cases the PVA: LAM ratio has an effect on the 
dissolution rate due to the matrix effect of the polymer. A quadratic term between milling 
time is also observed in the coefficient plots. 
 
Figure 1. The scaled and centered coefficient plots of the responses, where X1- milling 
time, X2- milling speed, X3- PVA: LAM (m/m %) ratio (X3). 
 
3.3.  Response Surface Plots 
3D surface plots were generated to graphically illustrate the relationship between the 
input variables and responses. It allows to understand the impact of interactions via estimating 
the expected responses depending to the change in variables. The quality of the surface is 
related to the value of Q2. The higher the value, the better the quality it has.  
In the case Y1 the response surface plots show, that the milling parameters have a 
nearly linear effect on the particle size. It presents that longer milling time and higher milling 
speed cause smaller particle size. The ranges of parameters to reach the desired response are 
quite wide, when the PVA:LAM ratios are 0.5 and 0.75. However, if the excipient: API ratio 
is 1 the desired particle size can not be achieved. As Y2 related to the size of LAM, the same 
can be drawn for SD. High PVA: LAM ratio resulted narrow optimal range and the desired 
target was possible to achieve in that case, when X3 was 0.75. A possible explanation of this 
phenomenon is that the PVA in higher concentration protects the LAM from the milling 
effect, therefore the balls can not decrease its particle size so easily.  
The reverse phenomenon can be seen on the contour plots of Y3 and Y4. High PVA: 
LAM ratio causes wider the optimal range due to the effect of PVA. PVA forms a matrix to 
the LAM particles from which they can release easier, if surface of the matrix is larger. The 
desired values of dissolution rate can not be achieved, when the ratio of applied materials are 
0.5 and 0.75- to reach the minimum requirement is possible-, but achievable when it is 1. The 
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variation range in the milling parameters is quite narrow as the target responses are difficult to 
reach.  
According to the response surface plots it can be concluded, that with high milling 
parameters the desired particle size (LAM particles below 250 nm) and SD can be reached, 
while the PVA: LAM ratio plays more important role in the dissolution of LAM. The surface 
plots underline the experiences gained during the study of scaled and centered coefficient 
plots. 
Figure 2. The surface plots shows the effect of the milling time (X1), the milling speed (X2) and 
PVA: LAM ratio (X3) on the responses, which are average particle size of LAM (Y1) and its 
standard deviation (Y2), the percentage of dissolved LAM from the samples after 5 (Y3) and 10 
minutes (Y4). 
3.4. Design Space 
Major objectives of QbD are risk minimization and design space development for the 
product. Design Space plots are generated by superimposing several contour plots and 
combining it with probability analysis [28-30]. Considering the models developed for the 
CQAs, Monte Carlo simulations were used to estimate the probability to meet the product 
specifications in the design region. The plot is a colour coded region and contour lines that 
have the role to separate the design region according to the probability of failure expressed in 
percentage (%) of failure. The green region, with low probability of failure is named the 
Design Space.    
The edges of the hypercube illustrating the generated PAR. The milling time was 
between 1.4 h and 1.7 h, while the PVA: LAM ratio was between 0.77 and 0.83 in the case of 
PVA/LAM ratio. The milling speed was kept constantly high, on 400 rpm as it had the 
narrowest variation range among the input variables and it had the highest influence on the 
responses according to the coefficient plots. The target values can be achieved using 
parameters between these ranges, that are nearby to 0 level in Table 1. MODDE can calculate 
a set point after running the optimizer that can estimate the tolerance available for the factors. 
During the setpoint analysis, a robustness estimate is calculated by adding disturbancers on 
the factors around the setpoint. In our study it was also our aim to find the robust set point. It 
is a solution with maximum factor ranges that will predict results inside the specifications. 
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Robust set point is actually the centre of the green region that is in our case 1.5 h milling time 
with 0.8 PVA: LAM ratio on 400 rpm speed. 
 
Figure 3. The Design Space of the dry milling method. The edges of the hypercube are 
between 1.4 h and 1.7 h in the case of milling time, 0.77 and 0.83 in the case of 
PVA/LAM ratio, respectively. Milling speed is kept constantly 400 rpm. The parameters 
of robust set point are 1.5 h, 400 rpm and 0.8 PVA/LAM ratio. 
 
3.5. Validation of Design Space 
As there are infinite good formulations it seemed to be the most rational to keep the 
PVA/LAM ratio at the robust set point. In the case of milling speed the interval was so narrow 
and lower speeds did not seem right previously, so it was kept on 400 rpm. Longer milling 
times than 1.5 h were not used, because in our previous study it was 2 hours and it was an aim 
to make the process time effective. After the evaluation of the results of P7 - that was 
prepared according to the robust set point and the results proved to be good- it would have 
been irrational to use higher milling times. The regions of DS were expressed in % of failure, 
the validation of it was designed based on these regions. The first sample was prepared 
outside the 50% probability of failure (P1), the second was in the region of 50% probability of 
failure (P2), the third was in the near edge of 10% probability of failure (P3), the fourth was 
in the region of 5% probability of failure (P4), the fifth was in the near edge of 1% probability 
of failure (P5), the sixth was inside the region of 0.5% probability of failure (P6) and the last 
one was prepared according to the robust set point (P7). Validation samples were prepared 
with PVA/LAM ratio 0.8 on 400 rpm and by using different milling times, that was varied 
according to the Table 3. 
 
Table 3. The experimental plan of Design Space validation. 
 
3.5.1. Particle size and morphology 
After the particle size determination (Table 4.) the following comments can be made: 
long milling time casues smaller mean size and standard deviation. This can be explained by 
the improving uniqueness of the LAM particles due to the milling. P7 sample showed the best 
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values in this case too with very small average particle size of LAM (97.46 nm). This small 
particle size, the homogenous distribution and the uniqueness of the LAM particles (Figure 4., 
B picture) causes that the API can leave the surface of the polymer easier. This property 
resulted the best dissolution rate among the tested samples. The only sample that did not 
correspond to the criteria (the target particle size of LAM was 250 nm) was P1, that can be 
explained by the short milling time. In the SEM picture of the sample (Figure 4., A. picture) 
heterogenous distribution, big sized particles and adhesion can be seen, that may lead to good 
dissolution, but due to these properties and high standard deviation, the reproducibility of the 
sample and these results are quite uncertain.   
Table 4. The results of particle size analysis.   
 
 
Figure 4. The SEM picture of sample P1 (A) and P7 (B).   
3.5.2. In vitro dissolution test 
The results of in vitro dissolution test can be seen in Table 5. They show that the 
highest amount of LAM was dissolved from the sample that was prepared according to the 
robust set point. 80.48% of the API dissolved from the sample after 5 minutes and 97.32% 
after 10 minutes, respectively. It means that only this formulation fulfilled the predefined 
target response values (< 85% dissolved LAM after 5 minutes, 100% dissolved LAM after 10 
minutes). The rest of the formulations performed also well during the test, but not counting 
P7, just two formulations (P1, P4) responded to the predetermined criteria of this test. An 
explanation of the unexpected good dissolution results in the case of P1 can be, that there are 
small particles that can leave the polymer matrix easy as well as the aggregated particles can 
deaggregate easy. However, these mechanisms can not be controlled that leads to uncertain 
reproducibility as it was mentioned above. The dissolution profiles of the samples can be seen 
in Figure 5.  




Figure 5. The in vitro dissolution profile of the powder formulations shows the dissolved amount 
of LAM during the investigation 
 
4. Conclusion 
The aim of this study was to determine and validate the Design Space of a previously 
used dry milling method for producing nasal powders that containing nanonized lamotrigine. 
The project was based on DoE, a tool of QbD with which the experiments can be planned 
more effectively, economically to provide more information from less number of 
experimental runs.  
It can be concluded that the predictions of optimal parameters were correct, because all 
of the samples reached the minimal predetermined response values. If not, it was expected as 
the sample P1 that had the highest % of failure and the results of its tests were outside the 
minimal criteria in the case of particle size determination. Thanks to the DS estimation a more 
economical –time and material effective- sample preparation method was set up. Sample 7 
that was prepared according to the robust set point (milling time: 1.5 h, milling speed: 400 
rpm, PVA: LAM ratio: 0.8) showed the best responses that yielded close to the target values 
of the CQAs. It had the smallest particle size as well as the smallest SD. The results of in vitro 
dissolution test showed that the highest amount of LAM dissolved from this sample that can 
be promising starting point for achieving rapid onset of action. The validation was successful, 
so powder 7 can be a strong base of the nasal powder development that will be further tested 
using in vitro (dissolution and permeability)- and in vivo investigations.  
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Figure 1. The scaled and centered coefficient plots of the responses, where X1- milling time, X2- 
























Figure 2. The surface plots shows the effect of the milling time (X1), the milling speed (X2) and 
PVA: LAM  ratio (X3) on the responses, which are average particle size of LAM (Y1) and its 







Figure 3. The Design Space of the dry milling method. The edges of the hypercube are between 
1.4 h and 1.7 h in the case of milling time, 0.77 and 0.83 in the case of PVA/LAM ratio, 
respectively. Milling speed is kept constantly 400 rpm. The parameters of robust set point are 
1.5 h, 400 rpm and 0.8 PVA/LAM ratio 
 
Figure 4. The SEM picture of sample P1 (A) and P7 (B).   
 
 
Figure 5. The in vitro dissolution profile of the powder formulations shows the dissolved amount 




Table 1. The parameters of milling, the chosen responses and their values 
Name Setting  Name Min Max Target 
Level -1 0 +1 
 
Mean size of LAM – 
Y1  350 nm 250 nm 
Milling time 
(h)- X1 0.5 1 2 
Standard Deviation– 
Y2  ± 200 nm ± 100 nm 
Milling speed 
(rpm)- X2 200 300 400 
Dissolved % LAM 
after 5 mins – Y3 70 %  85 % 
PVA: LAM 
ratio (m/m %)- 
X3 
0.5 0.75 1 Dissolved % LAM 
after 10 mins – Y4 85 %  100 % 
 
  
Table 2. Summary of fit for DoE, ANOVA Test results for model significance and lack of fit (p 
values) 
 
Response R2 Q2 Validity Reproducibility Model Significance Lack of fit test 
Y1 0.82 0.64 0.34 0.96 5.57E-06 0.073 
Y2 0.88 0.72 0.28 0.97 8.19E-07 0.057 
Y3 0.80 0.70 0.49 0.94 4.82E-08 0.285 
Y4 0.87 0.77 0.69 0.91 1.15E-08 0.115 
 
Table 3. The experimental plan of Design Space validation. 
 
Sample Milling time (h) Milling speed (rpm) PVA/LAM ratio 
(m/m %) 
Powder 1 (P1) 0.6 
400 0.8 
Powder 2 (P2) 0.9 
Powder 3 (P3) 1.0 
Powder 4 (P4) 1.1 
Powder 5 (P5) 1.2 
Powder 6 (P6) 1.3 
Powder 7 (P7) 1.5 
 
Table 4. The results of particle size analysis.   
Sample Y1- Mean size of LAM 
(nm) 
Y2- Standard Deviation (± 
nm) 
Powder 1 (P1) 521.42 310 
Powder 2 (P2) 212.77 150 
Powder 3 (P3) 198.71 120 
Powder 4 (P4) 143.36 80 
Powder 5 (P5) 124.18 60 
Powder 6 (P6) 140.62 70 








Table 5. The result of the in vitro dissolution rate study 
Sample Y3- Dissolved amount of LAM 
after 5 minutes (%) 
Y4- Dissolved amount of LAM 
after 10 minutes (%) 
Powder 1 (P1) 71.24 ± 3.19 87.47 ± 1.09 
Powder 2 (P2) 61.06 ± 6.03 73.78 ± 4.74 
Powder 3 (P3) 64.67 ± 6.14 73.27 ± 1.65 
Powder 4 (P4) 77.04 ± 3.00 89.52 ± 1.31 
Powder 5 (P5) 66.20 ± 3.33 72.03 ± 1.59 
Powder 6 (P6) 63.69 ± 3.48 76.63 ± 2.93 
Powder 7 (P7) 80.48 ± 3.66 97.32 ± 4.95 
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Supplementary table 1. Design matrix and results. Y1- mean particle size of LAM, Y2- Standard 
Deviation, Y3- Dissolved % LAM after 5 mins, Y4- Dissolved % LAM after 10 mins 
Experiment 
number X1 (h) X2 (rpm) X3 Y1 (nm) Y2 (± nm) Y3 (%) Y4 (%) 
1 0.5 200 0.5 1653.55 1431 25.98 36.97 
2 1 200 0.5 7015 3992 52.66 54.77 
3 2 200 0.5 1338.31 1811 35.67 36.92 
4 0.5 300 0.5 2442.67 1407 35.93 40.08 
5 1 300 0.5 867.73 442 43.1 49.12 
6 2 300 0.5 341.49 175 39.93 50.25 
7 0.5 400 0.5 216.58 135 49.32 58.71 
8 1 400 0.5 172.96 195 63.18 77.73 
9 2 400 0.5 142.602 11 71.75 89.08 
10 0.5 200 0.75 1079.33 637 17.85 23.91 
11 1 200 0.75 1016.89 563 68.93 65.51 
12 2 200 0.75 567.88 419 46.97 60.12 
13 0.5 300 0.75 748.09 327 32.29 32.62 
14 1 300 0.75 477.43 253 57.31 63.46 
15 2 300 0.75 212.19 107 79.97 91.72 
16 0.5 400 0.75 928.09 765 64.35 70.97 
17 1 400 0.75 223.13 133 80.91 96.46 
18 2 400 0.75 241.05 224 90.42 100 
19 0.5 200 1 1690 1137 23.25 22.77 
20 1 200 1 577.14 481 51.2 57.99 
21 2 200 1 949.9 1004 61.53 53.57 
22 0.5 300 1 1720 1302 38.75 43.27 
23 1 300 1 630.2 492 64.12 78.24 
24 2 300 1 1215.52 796 67.64 70.79 
25 0.5 400 1 311 142 67.06 89.33 
26 1 400 1 319.73 107 85.13 91.15 
27 2 400 1 361.05 116 66.26 84.21 
28 1 300 0.75 477.43 253 60.91 76.25 
29 1 300 0.75 353.78 175 64.06 65.75 
30 1 300 0.75 385.25 231 68.15 63.4 
 
